|Bid||0.00 x 800|
|Ask||0.00 x 1100|
|Day's Range||22.00 - 23.35|
|52 Week Range||21.16 - 56.59|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 06, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||49.00|
This morning, we issued a press release announcing our first-quarter 2021 financial results and business update. On today's call, Chris Martin, chief executive officer; Jennifer Herron, our chief commercial officer; Jay Feingold, chief medical officer; and Jenn Creel, chief financial officer, will discuss recent business highlights and review our first-quarter 2021 financial results before opening the call for questions.
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today reported financial results for the first quarter ended March 31, 2021 and provided business updates.
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced ZYNLONTA™ (loncastuximab tesirine-lpyl) has been included in the latest National Comprehensive Cancer Network® Clinical Practice Guidelines (NCCN Guidelines) in oncology for B-cell Lymphomas. Specifically, the NCCN Guidelines now include ZYNLONTA as a category 2A designation as a treatment option for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.